Prot #INCB50465-204: A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

Project: Research project

Project Details

StatusFinished
Effective start/end date1/24/18 → 1/24/21

Funding

  • Covance Inc. (Prot #INCB50465-204 // Prot #INCB50465-204)
  • Incyte Corporation (Prot #INCB50465-204 // Prot #INCB50465-204)